Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Johnson & Johnson proposes $6.5bn deal to settle talc claims

(Sharecast News) - Johnson & Johnson has proposed a $6.5bn deal to settle thousands of lawsuits claiming its talc products cause cancer, it was confirmed on Wednesday. Under the deal, J&J will pay out $6.5bn over the next 25 years. The company recorded a $2.7bn charge in the first quarter in expectations of the deal being backed, bringing total reserves for talc claims to around $11bn.

Should 75% of the plaintiffs approve the proposed settlement, the drugmaker will then be able to file for bankruptcy for LTL Management, the subsidiary created to absorb the talc liability.

J&J encouraged the remaining 60,000-plus plaintiffs with claims against it to vote in favour.

Eric Haas, worldwide vice president of litigation, said: "The plan is the culmination of our consensual resolution strategy that we announced last October.

"Since then the company has worked with counsel representing the overwhelming majority of talc claimants to bring this litigation to a close, which we expect to do through this plan."

However, J&J - which has consistently denied that any of its products contain asbestos or cause cancer - also reiterated its belief that the none of the talc-related claims against it have merit.

Said Haas: "The talc claims asserted against the company exemplify the egregious impact on US businesses from meritless litigation and extreme judgements obtained by the plaintiffs' bar."

Ovarian cancer accounts for around 99% of the claims.

A three-month period for plaintiffs to vote on the plan will now get underway.

Share this article

Related Sharecast Articles

Goldman Sachs downgrades SSP to 'sell', prefers WH Smith
(Sharecast News) - Goldman Sachs downgraded SSP on Monday to 'sell' from 'neutral' "on a relative basis" as it took a look at European travel concessions.
UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.